A Phase I, Open-label, Single-Centre Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration to Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Lanicemine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Dec 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.
- 21 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.